Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
- PMID: 7680493
- DOI: 10.1126/science.7680493
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
Abstract
Multiple sclerosis (MS) is thought to be an autoimmune disease mediated by T lymphocytes that recognize myelin components of the central nervous system. In a 1-year double-blind study, 30 individuals with relapsing-remitting MS received daily capsules of bovine myelin or a control protein to determine the effect of oral tolerization to myelin antigens on the disease. Six of 15 individuals in the myelin-treated group had at least one major exacerbation; 12 or 15 had an attack in the control group. T cells reactive with myelin basic protein were reduced in the myelin-treated group. No toxicity or side effects were noted. Although conclusions about efficacy cannot be drawn from these data, they open an area of investigation for MS and other autoimmune diseases.
Comment in
-
MS study yields mixed results.Science. 1993 Feb 26;259(5099):1263. doi: 10.1126/science.8446895. Science. 1993. PMID: 8446895 No abstract available.
Similar articles
-
Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis.Ann N Y Acad Sci. 1996 Feb 13;778:251-7. doi: 10.1111/j.1749-6632.1996.tb21133.x. Ann N Y Acad Sci. 1996. PMID: 8610978
-
Insights into the immunopathogenesis of multiple sclerosis.Immunol Res. 2002;25(1):27-51. doi: 10.1385/IR:25:1:27. Immunol Res. 2002. PMID: 11868933 Review.
-
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.J Clin Invest. 1996 Jul 1;98(1):70-7. doi: 10.1172/JCI118779. J Clin Invest. 1996. PMID: 8690806 Free PMC article. Clinical Trial.
-
T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.Clin Exp Immunol. 2003 Jan;131(1):155-68. doi: 10.1046/j.1365-2249.2003.02019.x. Clin Exp Immunol. 2003. PMID: 12519400 Free PMC article.
-
Immune tolerance to myelin proteins.Immunol Res. 2003;28(3):201-21. doi: 10.1385/IR:28:3:201. Immunol Res. 2003. PMID: 14713715 Review.
Cited by
-
Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.Front Immunol. 2021 Mar 29;12:657768. doi: 10.3389/fimmu.2021.657768. eCollection 2021. Front Immunol. 2021. PMID: 33854514 Free PMC article. Review.
-
Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis.Front Mol Neurosci. 2022 Nov 4;15:1019877. doi: 10.3389/fnmol.2022.1019877. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36407764 Free PMC article. Review.
-
Clinical potential of antigen-specific therapies in type 1 diabetes.Rev Diabet Stud. 2012 Winter;9(4):328-37. doi: 10.1900/RDS.2012.9.328. Epub 2012 Dec 28. Rev Diabet Stud. 2012. PMID: 23804270 Free PMC article. Review.
-
Multiple sclerosis therapy: an update on recently finished trials.J Neurol. 2007 Nov;254(11):1473-90. doi: 10.1007/s00415-007-0684-7. Epub 2007 Nov 15. J Neurol. 2007. PMID: 18004638 Review.
-
Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions?Springer Semin Immunopathol. 1995;17(1):77-87. doi: 10.1007/BF00194101. Springer Semin Immunopathol. 1995. PMID: 7482228 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
